CHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2025
0mins
Source: NASDAQ.COM
Opdivo Approval: Bristol Myers Squibb's Opdivo (nivolumab) has received a positive recommendation from the European Medicines Agency for use in combination with chemotherapy as neoadjuvant treatment for high-risk non-small cell lung cancer, based on favorable results from the CheckMate-77T trial.
Expansion of Product Portfolio: The company also announced the approval of a subcutaneous formulation of Opdivo and the launch of Cobenfy, an oral medication for schizophrenia, which is expected to enhance its revenue base amid competition from generics.
Analyst Views on ANIP
Wall Street analysts forecast ANIP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIP is 113.50 USD with a low forecast of 103.00 USD and a high forecast of 121.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 85.290
Low
103.00
Averages
113.50
High
121.00
Current: 85.290
Low
103.00
Averages
113.50
High
121.00
About ANIP
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
